Novo Nordisk's highly anticipated Wegovy weight-loss pill has officially launched in the United States. The rollout marks a milestone as the first oral glucagon-like peptide-1 (GLP-1) therapy for adults living with obesity or overweight alongside related medical conditions.
Ed Cinca, Senior Vice President for Marketing and Patient Solutions at Novo Nordisk, said in a press release: 'We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them. For many of them, that wait is over, as we can now offer the powerful efficacy of Wegovy.'
